他汀类药物使用降低晚期鼻咽癌患者放疗相关卒中风险
该队列研究利用台湾癌症登记数据库,评估标准同步放化疗期间使用他汀对晚期鼻咽癌患者缺血性卒中风险的影响。他汀组较非他汀组缺血性卒中调整风险比为0.70(95%CI 0.54-0.92;P<0.0107),亲水性和亲脂性他汀均显示保护效应,且累积日剂量和日剂量强度越高卒中风险越低。
要点
- 同步放化疗期间使用他汀与缺血性卒中风险降低相关,调整风险比为0.70(95%CI 0.54-0.92;P<0.0107)。
- 亲水性他汀(如普伐他汀)aHR 0.37(95%CI 0.17-0.85),亲脂性他汀(如阿托伐他汀)aHR 0.32(95%CI 0.21-0.50)。
- 累积日剂量较高四分位组卒中风险较低,日剂量>1组aHR 0.49(95%CI 0.31-0.63),日剂量≤1组aHR 0.59(95%CI 0.40-0.84)。
核心结论
- 研究提供证据支持在同步放化疗期间使用他汀可降低接受根治性同步放化疗的晚期鼻咽癌患者放疗相关卒中风险。
- 普伐他汀和阿托伐他汀显示显著降低卒中发生。
- 研究结果提示存在剂量-反应关系,他汀累积剂量和日剂量强度越高与卒中风险越低相关。
研究设计与样本
- 基于台湾癌症登记数据库的队列研究,采用逆概率治疗加权Cox回归分析,评估同步放化疗期间他汀使用与缺血性卒中风险的关联。
主要发现
- 他汀组较非他汀组缺血性卒中调整风险比为0.70(95%CI 0.54-0.92;P<0.0107)。
- 亲水性他汀如普伐他汀较非他汀使用的aHR为0.37(95%CI 0.17-0.85),亲脂性他汀如阿托伐他汀较非他汀使用的aHR为0.32(95%CI 0.21-0.50)。
- 累积日剂量较高四分位组卒中风险较低。
- 日剂量>1组卒中风险aHR为0.49(95%CI 0.31-0.63),日剂量≤1组aHR为0.59(95%CI 0.40-0.84)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This cohort study aimed to evaluate the impact of statin use on ischemic stroke risk in patients with advanced nasopharyngeal carcinoma (NPC) undergoing standard concurrent chemoradiotherapy (CCRT). METHODS: Using data from the Taiwan Cancer Registry Database, we conducted an inverse probability of treatment-weighted Cox regression analysis to examine the association between statin use during CCRT and ischemic stroke risk. RESULTS: The adjusted hazard ratio (aHR) for ischemic stroke in the statin group compared to the non-statin group was 0.70 (95 % CI: 0.54-0.92; P < 0.0107). This protective effect was observed across different statin classes, with hydrophilic statins such as pravastatin showing an aHR of 0.37 (95 % CI: 0.17-0.85) and lipophilic statins including atorvastatin displaying an aHR of 0.32 (95 % CI: 0.21-0.50) compared to non-statin use. Analysis of cumulative defined daily doses (cDDD) revealed a dose-response relationship, with lower stroke risk observed in higher quartiles of cDDD. Additionally, patients with a daily defined dose (DDD) > 1 had a reduced risk of stroke with an aHR of 0.49 (95 % CI: 0.31-0.63), while those with DDD ≤ 1 showed an aHR of 0.59 (95 % CI: 0.40-0.84). CONCLUSIONS: Our study provides evidence supporting the beneficial effects of statin use during the CCRT period in reducing radiation-induced stroke risk among patients with advanced NPC undergoing definitive CCRT. Notably, pravastatin and atorvastatin demonstrated significant reductions in stroke occurrence. Furthermore, the findings suggest a dose-response relationship, where higher cumulative doses and greater daily dose intensity of statin use were associated with a lower risk of stroke.
引用
- Lin CY, Chang CL, Lin KC, et al. Statin use reduces radiation-induced stroke risk in advanced nasopharyngeal carcinoma patients. Radiother Oncol. 2023. PMID: 38142934. doi:10.1016/j.radonc.2023.110067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。